- Home
- NMS vs PYPD Comparison
NMS vs PYPD Comparison
Compare NMS & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | PYPD |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 76.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMS | PYPD |
|---|---|---|
| Price | $11.80 | $4.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 12.0K | ★ 91.2K |
| Earning Date | 01-01-0001 | 02-11-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.21 | $2.30 |
| 52 Week High | $12.18 | $5.05 |
Technical Indicators
Market Signals| Indicator | NMS | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 65.58 |
| Support Level | $11.67 | $4.25 |
| Resistance Level | $11.90 | $5.05 |
| Average True Range (ATR) | 0.12 | 0.27 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 45.85 | 61.67 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.